Siolta Therapeutics, a leader in the development of live biotherapeutic products (LBPs), and Cowellnex Co. Ltd, a Kirin and Kyowa Kirin joint investment, have signed a preclinical joint research agreement to develop an LBP aimed at the prevention of necrotizing enterocolitis (NEC). This collaboration combines Siolta’s expertise in microbial science with Cowellnex’s institutional strength to advance research and establish treatments in microbiome drug discovery.
“We are delighted to start this research with Siolta, following our investment through Kirin’s CVC fund”
Health Technology Insights: VectorBuilder Powers FDA IND Approval of World’s First Umbilical Cord Blood-Derived Allogeneic CAR-T Product
NEC is a severe condition affecting premature infants, characterized by intestinal necrosis with high morbidity and mortality rates. Despite improvements in neonatal care, effective prevention and treatment of NEC remain challenging. Using Siolta’s unique LBP platform, this joint research aims to develop a product to prevent the occurrence of NEC.
“We are excited to collaborate with Cowellnex on this important research,” said Nikole Kimes, Ph.D., CEO of Siolta Therapeutics. “Our shared vision and complementary technologies provide a strong foundation for developing innovative biotherapeutics targeting NEC in vulnerable infant populations.”
Health Technology Insights: Care Access Makes No-Cost Heart & Kidney Health Screenings Available in Austin
“We are delighted to start this research with Siolta, following our investment through Kirin’s CVC fund,” stated Junko Nishimae, President of Cowellnex. “NEC is a critical unmet medical need globally, affecting the lives of newborns. We hope to create innovative preventive medicines through collaboration with Siolta, utilizing Kirin’s gut microbiota research and Kyowa Kirin’s pharmaceutical R&D expertise.”
Leveraging Siolta’s Precision Symbiotics Platform™, this joint research with Cowellnex is poised to accelerate the discovery and development of groundbreaking interventions that could significantly improve neonatal care.
Health Technology Insights: Trially AI Joins athenahealth’s Marketplace Program to Enroll Patients into Clinical Trials
To participate in our interviews, please write to our HealthTech Media Room at news@intentamplify.com
Source – businesswire
